

# The effect of nitrous oxide on the minimum alveolar concentration (MAC) and MAC derivatives of isoflurane in dogs

Debra A. Voulgaris, Christine M. Egger, M. Reza Seddighi, Barton W. Rohrbach, Lydia C. Love, Thomas J. Doherty

## Abstract

This study investigated the effects of 70% nitrous oxide ( $N_2O$ ) on the minimum alveolar concentration (MAC) of isoflurane (ISO) that prevents purposeful movement, the MAC of ISO at which there is no motor movement ( $MAC_{NM}$ ), and the MAC of ISO at which autonomic responses are blocked ( $MAC_{BAR}$ ) in dogs.

Six adult, healthy, mixed-breed, intact male dogs were anesthetized with ISO delivered via mask. Baseline MAC,  $MAC_{NM}$ , and  $MAC_{BAR}$  of ISO were determined for each dog using a supra-maximal electrical stimulus (50 V, 50 Hz, 10 ms). Nitrous oxide (70%) was then administered and MAC and its derivatives ( $N_2O$ -MAC,  $N_2O$ - $MAC_{NM}$ , and  $N_2O$ - $MAC_{BAR}$ ) were determined using the same methodology. The values for baseline MAC,  $MAC_{NM}$ , and  $MAC_{BAR}$  were  $1.39 \pm 0.14$ ,  $1.59 \pm 0.10$ , and  $1.72 \pm 0.16$ , respectively. The addition of 70%  $N_2O$  decreased MAC,  $MAC_{NM}$ , and  $MAC_{BAR}$  by 32%, 15%, and 25%, respectively.

## Résumé

Cette étude avait comme objectif d'évaluer chez des chiens les effets de 70 % d'oxyde nitreux ( $N_2O$ ) sur la concentration alvéolaire minimum (MAC) d'isoflurane (ISO) qui empêche les mouvements volontaires, la MAC d'ISO à laquelle il n'y a pas de mouvement moteur ( $MAC_{NM}$ ), et la MAC d'ISO à laquelle les réponses autonomes sont bloquées ( $MAC_{BAR}$ ).

Six chiens mâles intacts adultes de race mélangée ont été anesthésiés avec de l'ISO administré via un masque. Les valeurs de base de MAC,  $MAC_{NM}$  et de  $MAC_{BAR}$  d'ISO ont été déterminées pour chaque chien à l'aide d'un stimulus électrique supra-maximal (50 V, 50 Hz, 10 ms). De l'oxyde nitreux (70 %) fut ensuite administré et la MAC et ses dérivées ( $N_2O$ -MAC,  $N_2O$ - $MAC_{NM}$  et  $N_2O$ - $MAC_{BAR}$ ) déterminées à l'aide de la même méthodologie. Les valeurs des données de base de MAC,  $MAC_{NM}$  et  $MAC_{BAR}$  étaient respectivement  $1,39 \pm 0,14$ ,  $1,59 \pm 0,10$  et  $1,72 \pm 0,16$ . L'ajout de 70 % de  $N_2O$  a entraîné des diminutions de MAC,  $MAC_{NM}$  et  $MAC_{BAR}$  de 32 %, 15 % et 25 %, respectivement.

(Traduit par Docteur Serge Messier)

## Introduction

The minimum alveolar concentration (MAC) of an inhalational anesthetic is defined as the alveolar concentration at sea level at which there is no purposeful movement in 50% of patients in response to a supra-maximal stimulus (1–3). Recent studies in dogs have investigated MAC derivatives, such as the MAC at which there is no motor movement ( $MAC_{NM}$ ) (4) and the MAC at which the autonomic response to noxious stimuli is blocked ( $MAC_{BAR}$ ) (5,6).

Nitrous oxide ( $N_2O$ ) is a colorless, non-flammable gas that is used in humans for its analgesic, immobilizing, and anxiolytic effects (7–9). Compared with other inhalational anesthetics, however,  $N_2O$  is low in potency and is less potent in dogs than in humans. Reported MAC values for  $N_2O$  in dogs vary from 188% (2) to 222% (10) and  $N_2O$  is used primarily as an adjunct to volatile anesthetics for its MAC-decreasing properties. In a recent study, the authors found that 70%  $N_2O$  decreased the MAC,  $MAC_{NM}$ , and  $MAC_{BAR}$  of sevoflurane in dogs by 24%, 25%, and 35%, respectively (5).

The purpose of this study was to evaluate the effects of 70%  $N_2O$  on the MAC,  $MAC_{NM}$ , and  $MAC_{BAR}$  of isoflurane (ISO) in dogs. It was hypothesized that 70%  $N_2O$  would significantly decrease the MAC,  $MAC_{NM}$ , and  $MAC_{BAR}$  of ISO.

## Materials and methods

### Animals

Six adult (2 to 3 y of age), purpose-bred, mixed-breed, intact male dogs ( $14 \pm 1$  kg) were determined to be healthy based on physical examination. Food was withheld for 12 h before anesthesia, but access to water was allowed. Each dog was anesthetized once. The MAC,  $MAC_{NM}$ , and  $MAC_{BAR}$  were determined in that order for ISO alone (baseline) and then for ISO with 70%  $N_2O$  (treatment). This sequence of determination of MAC and its derivatives was used to expedite the process and is standard procedure in our laboratory.

The study protocol was approved by the Institutional Animal Care and Use Committee at the University of Tennessee and was

California Animal Rehabilitation, Santa Monica, California, USA (Voulgaris); Department of Small Animal Clinical Sciences (Egger), Department of Large Animal Clinical Sciences (Seddighi, Doherty), and Department of Biomedical and Diagnostic Sciences (Rohrbach), University of Tennessee, Knoxville, Tennessee, USA; Animal Emergency and Referral Associates, Fairfield, New Jersey, USA (Love).

Address all correspondence to Dr. Christine M. Egger; telephone: (865) 974-8387; fax: (865) 974-5554; e-mail: cegger@utk.edu

Received November 8, 2011. Accepted February 15, 2012.

carried out in accordance with the Guide for the Care and Use of Experimental Animals.

## Anesthesia

Anesthesia was induced with ISO (IsoFlo; Abbott Animal Health, Abbott Park, Illinois, USA) in oxygen delivered via mask from a circle breathing system. After tracheal intubation, anesthesia was maintained with ISO in oxygen (2 L/min) using a small animal anesthetic machine (North American Drager, Telford, Pennsylvania, USA). Ventilation was controlled to maintain the end-tidal carbon dioxide partial pressure ( $P_{E'}CO_2$ ) at between 35 to 45 mmHg. Arterial blood samples were drawn from each subject at the time of each MAC,  $MAC_{NM}$  and  $MAC_{BAR}$  determination to ensure that arterial carbon dioxide tension ( $PaCO_2$ ), arterial partial pressure of oxygen ( $PaO_2$ ), and acid-base status were within normal limits. Dogs were placed in lateral recumbency, a 20-ga cephalic catheter (MILA International, Erlanger, Kentucky, USA) was placed, and lactated Ringer's solution (Abbott Animal Health) was infused (3 mL/kg body weight per h).

End-tidal ISO ( $E'_{ISO}$ ), end-tidal  $N_2O$  ( $E'_{N_2O}$ ), and  $P_{E'}CO_2$  were monitored continuously with an infrared gas analyzer (Criticare Systems, Waukesha, Wisconsin, USA). Samples were drawn from the proximal end of the endotracheal tube at a rate of 150 mL/min. At the beginning of the study, the monitor was calibrated with the calibration gases supplied by the manufacturer (1% ISO in 5%  $CO_2$  and 60%  $N_2O$ ; Criticare Systems). Body temperature was monitored using an esophageal probe (Criticare Systems). A circulating warm water blanket and a warm air blanket (Bair Hugger; Arizant Healthcare, Eden Prairie, Minnesota, USA) were used to maintain body temperature within the normal range (37.5°C to 38.5°C). Arterial blood pressure was monitored continuously from a 20-ga catheter placed in a dorsal pedal artery, using a monitor (Criticare Systems) and a disposable transducer (Baxter Healthcare Corporation, Deerfield, Illinois, USA). The middle of the sternum was taken as the zero point for blood pressure measurement. Heart rate and electrocardiogram (ECG) were monitored continuously using a 3-lead system and hemoglobin saturation ( $SpO_2$ ) was monitored continuously using a tongue probe (Criticare Systems).

## Determination of baseline MAC

The determination of baseline MAC began approximately 45 min after induction of anesthesia and with the  $E'_{ISO}$  held constant at 1.5% for at least 15 min. A supra-maximal stimulus (50 V, 50 Hz, 10 ms) was delivered (Grass Instrument Company, West Warwick, Rhode Island, USA) via two 25-ga electrode needles inserted subcutaneously 5 cm apart over the mid-ulnar area. Two single stimuli with a 5-s interval were delivered initially, followed 5 s later by a continuous stimulus of 5 s duration, which was repeated after 5 s (11). Purposeful movement was defined as gross movement of the head or extremities. Twitching of the stimulated limb, coughing, swallowing, rigidity, tail movement, or chewing were not considered purposeful movements. If purposeful movement occurred, the  $E'_{ISO}$  was increased by 0.1% or 0.2% depending on the magnitude of the response; otherwise, it was decreased by 0.1% and the stimulus was reapplied after a 15-min equilibration period. The MAC was defined as the mean of the lowest  $E'_{ISO}$  at which purposeful movement did

and did not occur. All MAC values were determined in duplicate and the mean value was taken as the baseline MAC for that animal. If the difference between these values was greater than 10%, a third value was determined and the mean of these 3 values was taken as the baseline MAC for that animal.

## Determination of baseline $MAC_{NM}$

After MAC was determined, the  $E'_{ISO}$  was maintained at 1.5% for at least 15 min before the baseline  $MAC_{NM}$  was determined using the same methodology as for MAC. The  $MAC_{NM}$  was defined as the lowest  $E'_{ISO}$  at which there was no motor movement, purposeful or non-purposeful, in response to the noxious stimulus. Twitching of the stimulated limb was not considered a positive response.

## Determination of baseline $MAC_{BAR}$

After baseline  $MAC_{NM}$  was determined, the  $E'_{ISO}$  was maintained at 1.5% for at least 15 min before initiating baseline  $MAC_{BAR}$  determination. During each pre-stimulus period, heart rate (HR) and mean arterial pressure (MAP) values were recorded from the arterial line and were stable for at least 5 min, varying by less than 1%. The greatest HR and MAP values during this time period were taken as the baseline. The baseline  $MAC_{BAR}$  was determined using the same methodology as for MAC and  $MAC_{NM}$ .  $MAC_{BAR}$  was defined as the lowest  $E'_{ISO}$  that prevented a  $\geq 15\%$  increase in baseline MAP and HR in response to the noxious stimulus during the 60-s period beginning at the time of the first stimulus.

## Administration of $N_2O$

After baseline MAC,  $MAC_{NM}$  and  $MAC_{BAR}$  were determined, administration of 70%  $N_2O$  began. After a 15-min equilibration period with the  $E'_{N_2O}$  maintained at 70% and the  $E'_{ISO}$  at 1.5%, the treatment MAC endpoints ( $N_2O$ -MAC,  $N_2O$ - $MAC_{NM}$  and  $N_2O$ - $MAC_{BAR}$ ) were determined using the same methods previously described for the baseline MAC and its derivatives.

Time recording began immediately after the initial equilibration period and time to determination of MAC,  $MAC_{NM}$  and  $MAC_{BAR}$  was cumulative. The dogs were evaluated for tissue damage, lameness, and pain for 24 h after recovery.

## Statistical analysis

Percent change in MAC,  $MAC_{NM}$  and  $MAC_{BAR}$  was calculated according to the formula:

$$(\text{treatment value} - \text{baseline value}) / (\text{baseline value}) \times 100$$

A mixed-model analysis of variance (ANOVA) (PROC MIXED) was used to determine the effect of treatment on MAC,  $MAC_{NM}$  and  $MAC_{BAR}$ . Dog was included as a random factor in the model. Dog, treatment, and endpoint were included as class variables. Independent variables included treatment, endpoint, time, and the 2-way interaction between endpoint and treatment. A second mixed-model ANOVA was used to compare the percent change in MAC among endpoints (MAC,  $MAC_{NM}$  and  $MAC_{BAR}$ ). Class variables included in the model were dog and endpoint. Endpoint was the independent variable and dog was included as a random factor in the model. A multiple range test according to the method of Tukey was used to adjust for multiple comparisons. Fit of the models was

**Table I. Baseline and treatment MAC, MAC<sub>NM</sub>, and MAC<sub>BAR</sub> values of isoflurane and percent change in each value after adding 70% N<sub>2</sub>O in 6 male dogs**

MAC endpoint	Baseline	Treatment	% Change
MAC	1.39 ± 0.14 <sup>a</sup>	0.98 ± 0.14 <sup>b</sup>	-31.9 ± 3.3 <sup>1</sup>
MAC <sub>NM</sub>	1.59 ± 0.10 <sup>c</sup>	1.37 ± 0.10 <sup>c</sup>	-14.9 ± 3.3 <sup>2</sup>
MAC <sub>BAR</sub>	1.72 ± 0.16 <sup>d</sup>	1.31 ± 0.12 <sup>e</sup>	-24.9 ± 3.3 <sup>1</sup>

MAC — minimum alveolar concentration; MAC<sub>NM</sub> — minimum alveolar concentration at which there is no motor movement; MAC<sub>BAR</sub> — minimum alveolar concentration at which autonomic response is blocked.

<sup>a,b,c,d,e</sup> Values in the same row with different letters are significantly different.

<sup>1,2</sup> Values in the same column with different numbers are significantly different ( $P \leq 0.05$ ). All values are presented as least squares mean ± standard error of the mean.

evaluated using the -2 log likelihood ratio and the fit of residuals from the model to a normal distribution. Residuals were evaluated using the test statistic of Shapiro-Wilk. Effect of treatment on percent change in MAC at each endpoint was evaluated using a paired *t*-test [PROC UNIVARIATE]. Data are expressed as least squares means (LSM) and standard error of the mean (SEM). A *P*-value of  $\leq 0.05$  was considered significant.

## Results

The mean baseline values for MAC, MAC<sub>NM</sub>, and MAC<sub>BAR</sub> were 1.39%, 1.59%, and 1.72%, respectively (Table I). Administering 70% N<sub>2</sub>O decreased these values by 32%, 15%, and 25%, respectively. Baseline MAC<sub>NM</sub> was not significantly different than N<sub>2</sub>O-MAC<sub>NM</sub>. While the percent change in MAC<sub>BAR</sub> was not significantly different than the percent change in MAC, the percent change in MAC<sub>NM</sub> was significantly different than the percent change in MAC and MAC<sub>BAR</sub> (Table I). The estimated hemoglobin saturation was > 95% and PaO<sub>2</sub>, PaCO<sub>2</sub>, and acid-base status were normal at all times before and during administration of N<sub>2</sub>O. Recovery from anesthesia was uneventful and the dogs resumed normal activities within 2 to 3 h of recovery. The stimulated limbs appeared normal at all times.

## Discussion

In this study, administering 70% N<sub>2</sub>O decreased MAC, MAC<sub>NM</sub>, and MAC<sub>BAR</sub> (Table I). The baseline MAC value of 1.39% was comparable to the values reported for dogs in previous studies: 1.38% (12), 1.28% (13), and 1.34% (11). While interindividual variation in MAC values of 10% to 20% is typical (3), variation was minimized in this study by the use of only 1 observer. The MAC can also be affected by extremes of PaCO<sub>2</sub>, PaO<sub>2</sub>, body temperature, and arterial blood pressure. These variables were maintained within normal range in each patient throughout the experiment.

The addition of 70% N<sub>2</sub>O decreased the MAC by 32%, which is comparable with the MAC-sparing effects of N<sub>2</sub>O reported in previous studies. In halothane-anesthetized dogs, 75% N<sub>2</sub>O decreased MAC by 34% (10) and in sevoflurane-anesthetized dogs, 70% N<sub>2</sub>O

decreased MAC by 24% (5). In a clinical study of dogs undergoing ovariohysterectomy, a 37% decrease in requirement for isoflurane was reported when 64% N<sub>2</sub>O was included in the anesthetic protocol (14). These results are also consistent with the effects of N<sub>2</sub>O in other species. For example, 70% N<sub>2</sub>O decreased the MAC of isoflurane in rats by 40% (15) and 75% N<sub>2</sub>O decreased the MAC in swine by 38% (16). In desflurane-anesthetized dogs, however, 70% N<sub>2</sub>O decreased the MAC by only 16% (17). Differences among studies are likely due to individual variation, sample size, inhalational anesthetic, and experimental design.

The MAC<sub>NM</sub> in this study was 1.59% or 1.14 MAC (Table I). This ratio of MAC<sub>NM</sub>/MAC is comparable to the reported ratio of 1.16 for sevoflurane MAC<sub>NM</sub>/MAC in dogs (5). These data are also in general agreement with a study of human surgical patients, which reported that the E' ISO that prevented movement in 95% of the population was approximately 25% greater than the MAC (18). In contrast, a comparable endpoint in halothane-anesthetized ponies was equivalent to 1.6 MAC (19), which may reflect differences among species and inhalational anesthetics. The addition of 70% N<sub>2</sub>O decreased MAC<sub>NM</sub> by 15% (Table I), but there was wide variability among dogs. To the authors' knowledge, there are no published reports on the effect of N<sub>2</sub>O on MAC<sub>NM</sub> in dogs. In another study, the authors determined that 70% N<sub>2</sub>O decreased sevoflurane MAC<sub>NM</sub> in dogs by 25% (5).

In this study, baseline MAC<sub>BAR</sub> was 1.72% or 1.24 MAC (Table I). This endpoint is typically greater than the other MAC derivatives, as autonomic responses are activated at lower stimulus levels and are more resistant to blockade than movement responses (20). Suppression of this response may be clinically relevant because autonomic activation can have deleterious effects on the patient (20–22). There is limited information on MAC<sub>BAR</sub> in dogs and other veterinary species, and most MAC<sub>BAR</sub> studies in humans include N<sub>2</sub>O in the baseline anesthetic protocol, which makes it difficult to compare results. Recent studies by the authors reported MAC<sub>BAR</sub> values of 1.27 MAC (5) and 1.4 MAC (6) for sevoflurane. Reported MAC<sub>BAR</sub> values vary widely in other species. A study of isoflurane-anesthetized goats reported a MAC<sub>BAR</sub> of 2.8 MAC (23), but in cats anesthetized with isoflurane, the MAC<sub>BAR</sub> was only 1.1 MAC (24). In rats, the MAC<sub>BAR</sub> for sevoflurane did not differ significantly from the MAC (25), and MAC<sub>BAR</sub> values of 2.58 MAC (26) and 3.9 MAC (27) for sevoflurane have been reported in human female patients. Variations of such magnitude are likely due to the same factors as those discussed previously for MAC.

In the present study, the mean decrease in MAC<sub>BAR</sub> with the addition of 70% N<sub>2</sub>O was 25%. To the authors' knowledge, there are no published reports on the effect of 70% N<sub>2</sub>O on the MAC<sub>BAR</sub> of isoflurane in dogs. In a previous study, however, the authors found that 70% N<sub>2</sub>O decreased the MAC<sub>BAR</sub> of isoflurane by approximately 35% in dogs (5).

Decreases in MAC and its derivatives with N<sub>2</sub>O could be due to its analgesic and/or immobilizing effects. Although the mechanisms of action of N<sub>2</sub>O are not completely understood, its analgesic actions are likely separate from its immobilizing effects (9,28). Immobility during general anesthesia is mediated by motor neurons located in the ventral horn of the spinal cord (29,30). Interestingly, it has been shown that neurons in the ventral horn are more sensitive to the depressant effects of N<sub>2</sub>O than are neurons in the dorsal horn

(31). The immobilizing effects of N<sub>2</sub>O may be due to N-methyl-D-aspartate (NMDA) receptor blockade in the ventral horn (32,33), although mechanisms involving monoaminergic pathways have also been suggested (34).

Numerous mechanisms have been proposed to explain the analgesic actions of N<sub>2</sub>O. Although still controversial, prevailing evidence supports the involvement of opioid and alpha-2 adrenergic receptors (28,35,36). Specifically, nitrous oxide induces analgesia by activating opioidergic neurons in the periaqueductal gray matter and noradrenergic neurons in the locus coeruleus. This results in modulation of nociceptive transmission at the level of the spinal cord (7,37–39).

In this study, the decrease in MAC and its variants with the addition of 70% N<sub>2</sub>O ranged from 15% to 32%. It therefore appears that N<sub>2</sub>O provides a clinically important reduction in MAC. The difference in the magnitude of the effect of N<sub>2</sub>O on MAC and MAC<sub>NM</sub> is surprising because they are both presumably mediated at the level of the spinal cord. This difference may be due to the small sample size and variability among subjects.

In this study, the determination of MAC and its derivatives was not randomized. Determining MAC provides a starting point for the determination of MAC<sub>NM</sub> or MAC<sub>BAR</sub>, as previously published studies and experience have indicated that MAC<sub>NM</sub> and MAC<sub>BAR</sub> are usually higher than MAC (5,23,26,27). Determining MAC and its derivatives in this order expedites the process. The current study and a previous study (5) from our laboratory demonstrated that the time to determine MAC and its derivatives has no significant effect on outcome, although this does not completely rule out an effect of order of determination.

The benefits of administering N<sub>2</sub>O must be weighed against its potential adverse effects on patients, personnel, and the environment. The patient's oxygenation must be monitored continuously throughout the perioperative period, as hypoxemia is more likely when using N<sub>2</sub>O. Long-term exposure to N<sub>2</sub>O can have adverse effects on personnel, including bone marrow suppression, spontaneous abortion, teratogenicity, genotoxicity, and myelinopathies (39–41). In addition, N<sub>2</sub>O contributes to ozone depletion in the environment (40,41).

In conclusion, adding 70% N<sub>2</sub>O significantly decreased the MAC, MAC<sub>NM</sub>, and MAC<sub>BAR</sub> of isoflurane (ISO) in dogs by 32%, 15%, and 25%, respectively.

## Acknowledgment

The authors thank Abbott Animal Health for donating IsoFlo for this study. Abbott Animal Health had no role, however, in the study design; collection, analysis, or interpretation of the data; writing of the manuscript; or in the decision to submit the manuscript for publication.

## References

1. Merkel G, Eger EI 2nd. A comparative study of halothane and halopropane anesthesia including a method for determining equipotency. *Anesthesiology* 1963;24:346–357.
2. Eger EI 2nd, Saidman LJ, Brandstater B. Minimum alveolar anesthetic concentration: A standard of anesthetic potency. *Anesthesiology* 1965;26:756–763.
3. Quasha AL, Eger EI 2nd, Tinker JH. Determination and applications of MAC. *Anesthesiology* 1980;53:315–334.
4. Seddighi R, Egger C, Rohrbach B, Cox S, Doherty T. The effects of midazolam on the end-tidal concentration of isoflurane necessary to prevent movement in dogs. *Vet Anaesth Analg* 2011;38:195–202.
5. Seddighi R, Egger CM, Rohrbach BW, Hobbs M, Doherty TJ. The effect of nitrous oxide on sevoflurane MAC and MAC derivatives in dogs. *Am J Vet Res* 2012;73:341–345.
6. Love L, Egger C, Rohrbach B, Cox S, Hobbs M, Doherty T. The effect of ketamine on the MAC<sub>BAR</sub> of sevoflurane in dogs. *Vet Anaesth Analg* 2011;38:292–300.
7. Maze M, Fujinaga M. Pharmacology of nitrous oxide. *Best Pract Res Clin Anaesthesiol* 2001;15:339–348.
8. Emmanouil DE, Quock RM. Advances in understanding the actions of nitrous oxide. *Anesth Prog* 2007;54:9–18.
9. Jinks SL, Carstens E, Antognini JF. Nitrous oxide-induced analgesia does not influence nitrous oxide's immobilizing requirements. *Anesth Analg* 2009;109:1111–1116.
10. Steffey EP, Gillespie JR, Berry JD, Eger EI 2nd, Munson ES. Anesthetic potency (MAC) of nitrous oxide in the dog, cat, and stump-tail monkey. *J Appl Physiol* 1974;36:530–532.
11. Valverde A, Morey TE, Hernandez J, Davies W. Validation of several types of noxious stimuli for use in determining the minimum alveolar concentration for inhalation anesthetics in dogs and rabbits. *Am J Vet Res* 2003;64:957–962.
12. Yang XL, Ma HX, Yang ZB, et al. Comparison of minimum alveolar concentration between intravenous isoflurane lipid emulsion and inhaled isoflurane in dogs. *Anesthesiology* 2006;104:482–487.
13. Steffey EP, Howland D Jr. Isoflurane potency in the dog and cat. *Am J Vet Res* 1977;38:1833–1836.
14. Duke T, Caulkett NA, Tataryn JM. The effect of nitrous oxide on halothane, isoflurane and sevoflurane requirements in ventilated dogs undergoing ovariohysterectomy. *Vet Anaesth Analg* 2006;33:343–350.
15. Santos M, Kuncar V, Martinez-Taboada F, Tendillo FJ. Large concentrations of nitrous oxide decrease the isoflurane minimum alveolar concentration sparing effect of morphine in the rat. *Anesth Analg* 2005;100:404–408.
16. Tranquilli WJ, Thurmon JC, Benson GJ. Anesthetic potency of nitrous oxide in young swine (*Sus scrofa*). *Am J Vet Res* 1985;46:58–60.
17. Nishimori CT, Nunes N, Paula DP, Rezende ML, Souza AP, Santos PSP. Effects of nitrous oxide on minimum alveolar concentration of desflurane in dogs. *Arquivo Brasileiro de Medicina Veterinária e Zootecnia* 2007;59:97–104.
18. de Jong RH, Eger EI 2nd. MAC expanded AD<sub>50</sub> and AD<sub>95</sub> values of common inhalation anesthetics in man. *Anesthesiology* 1975;42:384–389.
19. Doherty TJ, Geiser DR, Frazier DL. Comparison of halothane minimum alveolar concentration and minimum effective concentration in ponies. *J Vet Pharmacol Ther* 1997;20:408–410.
20. Desborough JP. The stress response to trauma and surgery. *Br J Anaesth* 2000;85:109–117.

21. Ben-Eliyahu S, Page GG, Schleifer SJ. Stress, NK cells and cancer: Still a promissory note. *Brain Behav Immun* 2007;21:881–887.
22. Bartal I, Melamed R, Greenfeld K, et al. Immune perturbations in patients along the perioperative period: Alterations in cell surface markers and leukocyte subtypes before and after surgery. *Brain Behav Immun* 2010;24:376–386.
23. Antognini JF, Berg K. Cardiovascular responses to noxious stimuli during isoflurane anesthesia are minimally affected by anesthetic action in the brain. *Anesth Analg* 1995;81:843–848.
24. March PA, Muir WW 3rd. Minimum alveolar concentration measures of central nervous system activation in cats anesthetized with isoflurane. *Am J Vet Res* 2003;64:1528–1533.
25. Docquier MA, Lavand'homme P, Ledermann C, Collet V, De Kock M. Can determining the minimum alveolar anesthetic concentration of volatile anesthetic be used as an objective tool to assess antinociception in animals? *Anesth Analg* 2003;97:1033–1039.
26. Nakata Y, Goto T, Ishiguro Y, Terui K, Nimi Y, Morita S. Anesthetic doses of sevoflurane to block cardiovascular responses to incision when administered with xenon or nitrous oxide. *Anesthesiology* 1999;91:369–373.
27. Ura T, Higuchi H, Taoda M, Sato T. Minimum alveolar concentration of sevoflurane that blocks the adrenergic response to surgical incision in women: MAC<sub>BAR</sub>. *Eur J Anaesthesiol* 1999;16:176–181.
28. Koyama T, Fukuda K. Involvement of the kappa-opioid receptor in nitrous oxide-induced analgesia in mice. *J Anesth* 2010;24:297–299.
29. Rampil IJ, King BS. Volatile anesthetics depress spinal motor neurons. *Anesthesiology* 1996;85:129–134.
30. Jinks S, Bravo M, Hayes SG. Volatile anesthetic effects on mid-brain-elicited locomotion suggest that the locomotor network in the ventral spinal cord is the primary site for immobility. *Anesthesiology* 2008;108:1016–1024.
31. Kim J, Yao A, Atherley R, Carstens E, Jinks SL, Antognini JF. Neurons in the ventral spinal cord are more depressed by isoflurane, halothane, and propofol than are neurons in the dorsal spinal cord. *Anesth Analg* 2007;105:1020–1026.
32. Sonner JM, Antognini JF, Dutton RC, et al. Inhaled anesthetics and immobility: Mechanisms, mysteries, and minimum alveolar anesthetic concentration. *Anesth Analg* 2003;97:718–740.
33. Antognini JF, Atherley RJ, Dutton R, Laster MJ, Eger EI 2nd, Carstens E. The excitatory and inhibitory effects of nitrous oxide on spinal neuronal responses to noxious stimulation. *Anesth Analg* 2007;104:829–835.
34. Petrenko AB, Yamakura T, Kohno T, Sakimura K, Baba H. Reduced immobilizing properties of isoflurane and nitrous oxide in mutant mice lacking the N-methyl-D-aspartate receptor GluRε1 subunit are caused by the secondary effects of gene knockout. *Anesth Analg* 2010;110:461–465.
35. Guo TZ, Davies MF, Kingery WS, Patterson AJ, Limbird LE, Maza M. Nitrous oxide produces antinociceptive response via alpha 2<sub>B</sub> and/or alpha 2<sub>C</sub> adrenoceptor subtypes in mice. *Anesthesiology* 1999;90:470–476.
36. Sawamura S, Kingery WS, Davies MF, et al. Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of [alpha]2<sub>B</sub> adrenoceptors. *J Neurosci* 2000;20:9242–9251.
37. Zhang C, Davies MF, Guo TZ, Maze M. The analgesic action of nitrous oxide is dependent on the release of norepinephrine in the dorsal horn of the spinal cord. *Anesthesiology* 1999;91:1401–1407.
38. Fujinaga M, Maze M. Neurobiology of nitrous oxide-induced antinociceptive effects. *Mol Neurobiol* 2002;25:167–189.
39. Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: A mechanistic and toxicologic review. *Anesthesiology* 2008;109:707–722.
40. Myles PS, Leslie K, Silbert B, Paech MJ, Peyton P. A review of the risks and benefits of nitrous oxide in current anaesthetic practice. *Anaesth Intensive Care* 2004;32:165–172.
41. Ryan SM, Nielsen CJ. Global warming potential of inhaled anesthetics: Application to clinical use. *Anesth Analg* 2010;111:92–98.